Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > The Dilemma

<< Previous

Bullboard Posts

Next >>

Comment by enriquesuaveon Sep 12, 2021 4:39pm

474 Views

Post# 33846684

RE:The Dilemma

Hopefully next data readouts will show a clear picture of what TLD-1433 PDT can achieve and the market will take us way about warrants strike price. Warrants excercised would bring close to $7 million. Enough for the whole trial and more. If BTD comes in and AA is again on the table then definitely no worries All IMO

Johnandrose22 wrote: Perhaps the company’s equity price is indicative of a dilemma that long term share holders have experienced all too often. The company has indicated that the current phase 2 trial could last until 2024-2025. Despite its insistence, the company’s financial coffers do not necessarily equate to those stated target dates.

Thus...the dilemma...where will the money be generated to accomplish the company’s goals? It seems the market is telling us another PP is probably more realistic than a JV or even a buyout.

And so it is...I never thought I’d be thinking this (or even writing it) when I first invested in 2014.

John